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Writing a text on cancer genetics is a daunting task today
because of the amount of material to be covered and the speed
with which the field is developing and changing. Even in this
dynamic environment, there is some solid ground beginning
to emerge. This multiauthored, edited text is organized into
three parts in an effort to summarize what is currently known.
Part 1 focuses on selected aspects of the molecular biology and
natural history of hereditary breast and ovarian cancer. Part
2 deals with current screening recommendations and other
clinical service issues. Part 3 covers medical management, ethi-
cal, legal, social, and psychological issues for those women
found to be at increased risk. The intended audience is broad:
clinical geneticists, surgeons, oncologists, psychologists, and
other health care and health policy professionals. The authors
are largely experts from European centers, with contributions
from a few highly regarded North American scientists.
From the introduction, we learn that cancer genetics clinics
have been established in many parts of Europe for a number
of years but that the organization and quality of services vary.
They are becoming overwhelmed by increasing public demand
and consequent referrals. Eleven centers in Europe worked to-
gether in the late 1990s on an EU-funded demonstration pro-
ject entitled “Familial Breast Cancer: Audit of a New Devel-
opment in Medical Practice in European Centers.” The work
of the demonstration project continues as the “International
Collaborative Group on Familial Breast and Ovarian Cancer.”
The chapters included in this text were generated, in part, from
the work of the initial collaboration, which provided evidence
summaries, management guidelines, and consensus views for
various aspects of care for high-risk patients. Other chapters,
from independent investigators not affiliated with the European
demonstration project, produce a well-rounded text.
Part 1 contains up-to-date summary material that is con-
venient to have placed all “under one roof.” There are concise
summary chapters, which provide overviews of the clinical ge-
netics of breast cancer and ovarian cancer. It is gratifying to
see the inclusion of Charis Eng’s authoritative chapter onCow-
den syndrome, a rare condition, which provides interesting
clinical and scientific insights and which reminds readers that
BRCA1 and BRCA2 are not the only genes associated with
hereditary breast cancer. This high academic standard is con-
tinued in the Vasen and Nooy review regarding the question
of whether breast and ovarian cancers are part of hereditary
colorectal cancer susceptibility syndromes, including hereditary
nonpolyposis colorectal cancer (HNPCC) and Peutz-Jeghers
syndrome (PJS). There is no agreement on whether breast can-
cer is a component malignancy of HNPCC; however, there is
no doubt that ovarian cancer risk is increased in women with
HNPCC. The most frequently occurring cancers in PJS are
those of the colon and breast, but ovarian cancer is seen oc-
casionally in this hereditary colon cancer syndrome also. Other
chapters cover the natural history and pathology of hereditary
breast and ovarian cancers. This section concludes with a chap-
ter on estimating the risk of developing breast/ovarian cancer
by means of the Gail and Claus models and pedigree analysis,
augmented by Bayesian analysis. One shortcoming is that the
review does not consider the computer model BRCAPRO or
several other, more recent models included in the CancerGene
software program, which is now widely used by cancer genetic
counselors in the United States.
Part 2 is entitled “Screening,” but that proves rather a mis-
nomer, as the majority of the chapters relate to public health
issues regarding cancer genetics services in Europe. The ma-
terial in this section provides readers a window into the world
of cancer genetics services outside of the resource-rich United
States—for example, a Welsh model from Cardiff. This paper
has many helpful summary boxes which highlight key points
throughout the text. For example, a summary of benchmarks
being piloted for cancer genetics service provision could serve
as a checklist for other programs interested in measuring the
quality of their service. Other service-related chapters focus on
referral criteria and guidelines for the development of cancer
genetics services, with an emphasis on preliminary risk assess-
ment by the primary care provider, with the specialist services
reserved for known familial cases. The chapter byHaites,Hodg-
son, and the Scottish Working Group on developing clinical
cancer genetics services has detailed organizational suggestions,
such as a five-step evaluation strategy from initial risk assess-
ment through cancer genetics referral to risk reducing and
treatment suggestions. This model includes algorithms for risk
stratification and counseling of women at low, medium, and
high risk of breast, ovarian, and colon cancer. The final chap-
ters in this section, which focus on screening, detection, and
survival patterns for high-risk breast and ovarian cancer, form
an effective transition between this and the final section of the
book, which is devoted to management issues.
Part 3 includes chapters targeting women carrying BRCA1/
2 mutations, familial ovarian cancer, and prophylactic mas-
tectomy. The issues of uptake and measurement of BRCA1/2
testing and other ethical, social, and insurance issues are ad-
dressed. The final chapters describe potential gene therapy op-
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tions and future research directions, which is generally an at-
tempt to include material that was published between first drafts
of manuscripts and the time of publication. Although this in-
formation is interesting and important, much of it is available
elsewhere, albeit in piecemeal fashion. For those looking for
comprehensive reviews of medical and psychosocial issues, in-
cluding references up to and including the year 2000, the man-
agement section will be extremely useful.
Over all, the text is very readable for a general scientific
audience. It may be rather technical for policy analysts and
health system administrators, but they will be rewarded for their
effort, since much of the information directly applies to organi-
zation of an important segment of health services. This edited
text covers all of the major areas of interest in considering
familial and hereditary breast and ovarian cancers. Although
the editors, most authors, and the focus on services are Eu-
ropean, there are enough commonalities to make the book a
worthwhile purchase for North American readers as well.
JUNE PETERS
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National Cancer Institute
Rockville, MD
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There has been considerable focus on the implications of the
Human Genome Project for the day-to-day practice of medi-
cine recently—both in the popular press and the medical lit-
erature. New research results are distilled into 10-second seg-
ments on the local evening news, and companies offering various
forms of clinical genetic testing have embarked on direct-to-
primary–care-provider and direct-to-consumer marketing of
their wares. Although it is still not clear just what the impact
of genomics will be on the diagnosis and treatment of many
common diseases, one thing is clear: there is an urgent need
to educate medical care providers about both the capabilities
of and—probably more importantly—the limitations of “ge-
nomic medicine.”
It is in this context that this book emerges. Written by a
molecular biologist/bioinformatics expert from the Department
of Cell Biology at the NewYork University School ofMedicine,
this book evolved from the author’s experience teaching an
elective medical genomics course offered to NYU medical stu-
dents. The book jacket suggests that it is being marketed in an
attempt to educate physicians and medical students regarding
emerging genomic technologies and “their role in clinical prac-
tice.” I believe that this book succeeds in meeting the former
goal but falls short of the mark on the latter goal.
At 274 pages, this text is organized into a total of 11 chap-
ters, plus a glossary and index. An introductory chapter, titled
“Deciphering the Human Genome Project,” reviews the basics
of Mendelian genetics and touches on topics including recom-
bination, linkage, transcription, translation, and alternative
splicing. The second chapter, entitled “Genomic Technology,”
discusses the basics of molecular biology from which today’s
high-throughput techniques have evolved.
Of particular note are chapters on bioinformatics tools and
genome databases. The former provides an excellent concise
summary of many of the tools available for in silico genome
analysis. The chapter on genome databases provides solid back-
ground regarding the information currently available in the
public domain. The author discusses various National Center
for Biotechnology Information (NCBI) resources, includingGen-
Bank, Entrez, PubMed/Medline, OMIM, and BLAST. A section
on genome annotation is useful. Also, illustrations give the
reader a taste of the human genome sequence data that can
be accessed over the Web by anyone with a computer. Lastly,
the author discusses model organisms and the potential of
comparative genomic studies to improve our knowledge of
the human genome.
A chapter on human genetic variation introduces concepts,
including different types of mutations, single-nucleotide poly-
morphisms, variable number tandem repeats, and linkage. The
chapter is sprinkled with a few clinical anecdotes.
The chapter entitled “Genetic Testing for the Practitioner”
was contributed by Dr. Harry Ostrer. Although it is an excel-
lent brief summary of issues surrounding genetic testing in the
clinic, I was really struck by the fact that only 11 pages of
relatively large-print text (out of 274 total pages) were devoted
to this subject in a book that is marketed primarily to current
and future clinicians. Although genomic medicine is a young
and evolving science, the clinical use of genetic testing is both
relevant and mature enough that I believe it deserves more
detail. I believe that the book would have benefited substan-
tially from the further involvement of Dr. Ostrer or other cli-
nicians. Of note, several concepts of real current importance to
the clinician were not covered here: mosaicism and imprinting
are two examples.
The other chapter by an outside contributor, an excellent re-
view of gene therapy, was contributed by Dr. John Hay. How-
ever, this chapter, at 32 pages in length, occupies almost 14%
of the book’s text—probably an allocation that is a little out
of proportion in comparison with the 11 pages devoted to
testing technologies already of clinical importance in nonre-
search settings.
The last several chapters do provide for a strong finish. Ex-
cellent chapters on microarrays and proteomic technologies al-
low the reader to understand these technologies, which will
almost certainly have an impact on clinical medicine in the
decades to come. Likewise, a chapter on pharmacogenomics and
toxicogenomics is well done. The final chapter is an excellent
discussion of some of the ethical, legal, and social issues found
at the intersection of emerging genomic technologies and the
clinic.
Lastly, the inclusion of a glossary is obviously quite impor-
tant in a book of this nature. Although the glossary is well
